Skip to main content
AIMD
NASDAQ Life Sciences

Ainos, Inc. Unveils Long-Term AI SmellTech Platform Strategy

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.75
Mkt Cap
$12.22M
52W Low
$1.61
52W High
$5
52W Position info
8.7% above low
Off High info
65% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

AIMD is trading near its 52-week low of $1.61 (8.7% above the low).

Summary

Ainos, Inc. announced a long-term strategy to digitize smell for AI, featuring proprietary hardware and a new AI software subsidiary, ScentAI Inc., which is developing a Smell Language Model.


Key Events · Product Development and Regulatory · AIMD

  • Long-Term SmellTech Platform Strategy

    Ainos, Inc. announced a long-term platform strategy to digitize smell and establish scent as a native data language for artificial intelligence.

  • Proprietary AI Nose Hardware

    The company will design, manufacture, and deploy its proprietary AI Nose sensing hardware, maintaining control over sensor design and manufacturing.

  • ScentAI Inc. Subsidiary Formed

    A wholly-owned AI software subsidiary, ScentAI Inc., will operate as the intelligence layer, focusing on AI model development and creating a Smell Language Model (SLM).

  • 2026 Scaled Deployment Plans

    In 2026, the company plans to transition from validation to scaled deployment, initially targeting advanced semiconductor manufacturing and robotic applications.


Analysis · AIMD · Life Sciences

Ainos, Inc. has outlined a comprehensive long-term strategy to establish scent as a native data language for artificial intelligence, a significant move for a company of its size. This strategy involves both proprietary AI Nose sensing hardware and a dedicated AI software subsidiary, ScentAI Inc., which is developing a Smell Language Model (SLM). This structural separation aims to enhance platform clarity and scalability. The planned transition to scaled deployment in 2026, with an initial focus on advanced semiconductor manufacturing and robotics, provides a clear roadmap for the company's future growth and technology commercialization.

At the time of this filing, AIMD was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $1.61 to $5.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIMD - Latest Insights

AIMD
Jul 24, 2026, 12:16 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.39 info
Change: -$0.125 (-8%) info
Market Cap: $11.167M info
AIMD
Jul 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.89
Real-time Price: $1.39 info
Change: -$0.500 (-26%) info
Market Cap: $11.167M info
AIMD
May 20, 2026, 8:00 AM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $1.60
Real-time Price: $1.39 info
Change: -$0.210 (-13%) info
Market Cap: $11.167M info
AIMD
May 13, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.85
Real-time Price: $1.39 info
Change: -$0.460 (-25%) info
Market Cap: $11.167M info
AIMD
May 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.39 info
Change: -$0.460 (-25%) info
Market Cap: $11.167M info